ACT have induced the highest rates of objective responses in melanoma patients (~25% and ~50%, respectively). [2] [3] [4] The rationale for this combination stems from the fact that the PD-1 pathway greatly contributes to immunosuppression in the tumor microenvironment, and hence presumably plays a role in the lack of clinical responses observed in some patients treated with ACT. Moreover, tumorreactive T-cells used for adoptive transfer frequently express the inhibitory PD-1 receptor.
Similar to what is observed in cancer patients, in our pre-clinical ACT model we observed the upregulation of PD-1 by adoptively transferred tumorspecific T cells at the tumor site, but not in peripheral blood or lymphoid organs. Given that interferon γ (IFNγ) has been reported to upregulate the expression of PD-L1 by tumor cells in vitro, it is reasonable to expect that IFNγ produced by T cells would increase PD-L1 expression by malignant cells in vivo. These observations suggest that the activation of the PD-1 pathway serves as an important checkpoint influencing the effectiveness of ACT. 5, 6 Therefore, we hypothesized that combining PD-1 checkpoint blockade and ACT may lead to therapeutic synergy and hence to higher rates of complete and durable responses.
To test this hypothesis, we treated gp100-expressing tumor-bearing mice with adoptively transferred pmel-1 T cells that express a TCR specifically recognizing a gp100-derived peptide in an H-2D b -restricted manner. 7 In two gp100-expressing tumor models, we found that mice treated with a combination of anti-PD-1 antibodies and ACT consistently showed increased numbers of transferred T cells at the tumor site and enhanced tumor regression, compared with mice treated with either agent alone. Although anti-PD-1 antibodies did not alter the number of immunosuppressive regulatory T cells (Treg) or myeloid-derived suppressor cells (MDSCs), blockade of the PD-1 pathway resulted in increased production of IFNγ as well as of the IFNγ-inducible chemokine CXCL10. Our findings concur with recent data showing that anti-PD-1 antibodies can enhance IFNγ production at the tumor sites of mice receiving an anticancer vaccine. 8 More interesting, our bone marrow chimera experiments with Ifngr1 −/− mice and CXCL10-deficient mice implicated IFNγ-CXCL10 as a major nexus point in the control of PD-1 blockade-induced tumor infiltration by T cells. Although CXCL10 is secreted by various cell types, including neutrophils, monocytes and dendritic cells, we found that CD11b + myeloid cells that share the blockade of the PD-1 pathway can increase the production of interferon γ by tumor-specific t cells located within or in the proximity of the malignant lesion, thereby increasing the chemokine-dependent trafficking of immune effector cells. this can boost the efficacy of adoptive t-cell therapy to achieve superior antitumor responses.
cells, thus leading to an improved antitumor response. (Fig. 1) Our preclinical results imply that immunotherapeutic regimens combining anti-PD-1 antibodies with ACT may achieve superior clinical responses in cancer patients. It will be interesting to test this approach in the context of oncogene-targeted (e.g., vemurafenib-based) some surface markers with granulocytic MDSCs are the major source of CXCL10 in the tumor microenvironment of these models. Collectively, these data suggest that anti-PD-1 therapies may re-educate MDSCs, an important immunosuppressive cell population of the tumor microenvironment, to favor the recruitment of adoptively transferred, tumor-specific T therapies, as it is possible that-in response to immunostimulatory signals-tumor-reactive T cells might be able to control the growth of drug-resistant tumor cells.
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